Is the Quoin Pharmaceuticals (QNRX) investment thesis intact?

Yes. Readouts currently rates the Quoin Pharmaceuticals Thesis Intact. QRX003 topline expected in second quarter of 2027; full results remain decisive.

What is the next catalyst for Quoin Pharmaceuticals (QNRX)?

The next dated event is Phase 3 start for QRX003, expected H2 2026, as stated by the company. Also ahead: IND submission for QRX009, expected before the end of 2026.

How long will Quoin Pharmaceuticals' cash last?

Quoin Pharmaceuticals has said its cash will fund operations into 2028 (guidance as of November 6, 2026). It reported $33.2 million in cash as of September 30, 2026.

QNRXQuoin Pharmaceuticals, Ltd.

⚡

Quoin Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2026 Financial Results - GlobeNewswire

GlobeNewswire · Nov 5, 1:30 PM

Market reactionShares fell 11% on Nov 2.

IntactLast material event Jul 9, 2026 · Updated Oct 20, 2026

QRX003 topline expected in second quarter of 2027; full results remain decisive

Quoin Pharmaceuticals is a clinical-stage company developing QRX003 (proposed brand QYLEKI), a lotion for Netherton syndrome and peeling skin syndrome, rare genetic skin diseases with no approved treatment; it is not approved.

Quoin's case depends on QRX003's Phase 2/3 Netherton results supporting an NDA. Four of six participants met the interim primary endpoint after 12 weeks; topline data are expected in the second quarter of 2027. Extended pediatric compassionate-use experience adds support, but involves one patient receiving add-on treatment. Peeling skin syndrome and QRX009 offer expansion opportunities. August financing provided for approximately $30.8 million upfront; additional warrant funding remains optional, and management's funding projection assumes cash exercise of all accompanying warrants.

Thesis checklist

0 risks need attention

Select a row for evidence

What must be trueStateNext proof

CL-QRX003-004 confirms the interim resultAwaiting evidenceRecruitment completion, followed by full CL-QRX003-004 efficacy and safety results and clarity on NDA adequacy.Next: Recruitment completion, followed by full CL-QRX003-004 efficacy and safety results and clarity on NDA adequacy.

Why it is in this state

The evidence, what would weaken it and the source filing

The peeling skin syndrome Phase 2/3 startsAwaiting evidenceFirst patient dosing in the planned peeling skin syndrome Phase 2/3 before year-end 2026.Next: First patient dosing in the planned peeling skin syndrome Phase 2/3 before year-end 2026.

Why it is in this state

The evidence, what would weaken it and the source filing

Cash reaches the NDAAwaiting evidenceUpdated cash balance, actual warrant receipts, and a funding outlook excluding unexercised warrants.Next: Updated cash balance, actual warrant receipts, and a funding outlook excluding unexercised warrants.

Why it is in this state

The evidence, what would weaken it and the source filing

Next decision point

Do full Netherton results confirm the interim response?

Tests: CL-QRX003-004 confirms the interim result

Topline data expected in the second quarter of 2027.

Does the full Phase 2/3 show consistent clinical benefit and acceptable safety sufficient to advance the NDA case?

Strong, inconclusive and weak outcomes

What to look for in the result and how each would move the checklist

Questions to investigate

History

Price and material events

Select an event marker to read the update below. Marker colors show Thesis status.

IntactCurrentRegulatory

-4.7%Jul 9, 2026

QRX003 topline expected in second quarter of 2027; full results remain decisive

IntactRegulatory

-26.3%Jun 23, 2026

Rare skin disease pioneer with no approved competitors races Phase 3 completion on thin runway, with NDA viability hinging on single-study sufficiency

IntactFinancial

+151.2%Oct 15, 2025

Private Placement Financing of $104.5M (upfront + warrant exercise)

About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.

Pipeline

Netherton Syndrome

QRX003 · 5 upcoming · 3 completed

Priority Review

2026

Phase 2 Data: ToplineCL-QRX003-002Pivotal

Dec 31, 2026

Phase 3 Study InitiationPivotal

H2 2026

Phase 3 Data: ToplineCL-QRX003-004Pivotal

Q2 2027

NDA Submission

2027

Additional indication (unspecified)

QRX009 · 1 upcoming

IND Submission

before the end of 2026

Microcystic Lymphatic Malformations· Venous Malformations

Topical rapamycin · 1 upcoming · 1 completed

Study Initiation

H2 2026early 2027

Peeling Skin Syndrome

QRX003 · 2 upcoming · 1 completed

Phase 2/3 Data: Interim

TBD

Approval

2028

Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.

Quick answers

Is the Quoin Pharmaceuticals (QNRX) investment thesis intact?: Yes. Readouts currently rates the Quoin Pharmaceuticals Thesis Intact. QRX003 topline expected in second quarter of 2027; full results remain decisive.
What is the next catalyst for Quoin Pharmaceuticals (QNRX)?: The next dated event is Phase 3 start for QRX003, expected H2 2026, as stated by the company. Also ahead: IND submission for QRX009, expected before the end of 2026.
How long will Quoin Pharmaceuticals' cash last?: Quoin Pharmaceuticals has said its cash will fund operations into 2028 (guidance as of November 6, 2026). It reported $33.2 million in cash as of September 30, 2026.

Other companies we cover in these diseases

Microcystic Lymphatic Malformations: Palvella Therapeutics (PVLA)

Disease areas: Neurology and pain, Skin diseases, Autoimmune and inflammatory diseases, Rare genetic and metabolic diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes

Competitive landscape

4 peers tracked

Financial snapshot

Dates and calculation details

Cash: Market-data provider estimate; measurement period unavailable.

Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.

Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.

Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.

Runway: No underlying guidance available.